BioCryst Pharmaceuticals, Inc. announced that the FDA has approved Rapivab (peramivir injection), an intravenous (i.v.) neuraminidase inhibitor for the treatment...
BioCryst Pharmaceuticals, Inc. announced that the FDA has approved a supplemental New Drug Application for Rapivab (peramivir injection), an intravenous...
BioCryst Pharmaceuticals announced that the European Medicines Agency (EMA) has accepted the filing of its Rapivab (peramivir) Marketing Authorization Application...
BioCryst Pharmaceuticals announced that the European Medicines Agency (EMA) has approved Alpivab (peramivir), a single intravenous (I.V.) infusion for the...